In-person Focus Groups in the Management of Urinary Incontinence in Women
The purpose of this study is to investigate how a support group with other individuals who share the condition urinary incontinence (UI) impacts patients experience with management of urinary incontinence.
|Condition or Disease||Intervention/Treatment||Phase|
Focus groups in various settings have demonstrated the ability to alleviate psychological and physiological distress in focus group participants. The exploration of focus groups is warranted to measure the potential benefit for patients with urinary incontinence. Researchers aimed to assess the feasibility and acceptability of in-person focus groups as a potential intervention for female patients with urinary incontinence from a mixed methods approach. A mixed methods pilot study will be conducted to investigate whether in-person focus group demonstrate meaningful significance in quantitative outcomes measured by validated questionnaires and qualitative outcomes analyzed from focus group transcripts and post-session surveys. This study was an initial assessment to determine whether in-person focus groups for females with UI is strong enough to warrant further research and clinical implementation.
Primary Outcome Measures
- Change in mixed urinary incontinence symptoms [Baseline, 12 weeks]
Measured using the Medical, Epidemiological, and Social Aspects of Aging (MESA) incontinence questionnaire which consists 15 questions to measure urgency of urinary incontinence and stress urinary incontinence on a 0-3 scale (0=Never, 3=Often). Higher total scores indicating higher severity of urge and stress incontinence.
- Change in urinary distress [Baseline, 12 weeks]
Measured using the Urogential Distress Inventory-6 (UDI-6) questionnaire which consists of 6 questions that rate urinary distress experience and how much it subjects are bothered by them on a 0-3 scale (0=not at all; 3=greatly).
- Change in overactive bladder satisfaction with treatment [Baseline, 12 weeks]
Measured using the Overactive Bladder Satisfaction with Treatment Questionnaire (OAB-SAT-q) which consists of 11 questions rating satisfaction or dissatisfaction with treatment for overactive bladder.
- Change in urinary tract condition severity [Baseline, 12 weeks]
Measured using the Patient Global Impression of Severity (PGI-S) questionnaire which consists of one question that asks subject to describe urinary tract condition currently on a scale of 1=normal, 2=mild, 3=moderate, 4=severe.
- Change in urinary tract condition improvement [Baseline, 12 weeks]
Measured using the Patient Global Impression of Improvement (PGI-I) questionnaire which consists of one question that asks subject to rate urinary tract condition currently, compared with how it was before taking medication on a scale of 1-7 (1=very much better; 7=very much worse)
- Change in sexual quality of life [Baseline, 12 weeks]
Measured using the Sexual Quality of Life Questionnaire- Female (SQoL-F) which consists of 18 questions to assess the relationship of sexual dysfunction and quality of life on a scale of 1-6 (1=completely agree; 6=completely disagree. Higher total scores indicate greater quality of life.
- Change in Patient Health Questionnaire [Baseline, 12 weeks]
Measured using the Patient Health Questionnaire (PHQ-9) which consists of 9 questions to assess depressive symptoms using a scale of 0-3 (0=not at all; 3=nearly every day). Higher total scores indicate greater severity depression.
- Change in physical activity [Baseline, 12 weeks]
Measured using the International Physical Activity Questionnaire (IPAQ) to assess physical activity as part of everyday life.
Secondary Outcome Measures
- Measure feasibility and acceptability of focus group [Baseline, 2 weeks, 4 weeks]
written survey was administered at the beginning of each focus group session which incorporated open-ended warm-up questions regarding urinary incontinence and concluded with the assessment of the level of focus group comfort on a scale from 1-5
18 years or older
Have the ability to commute to the meeting facility without institutional assistance
• Those unable to attend all three focus group sessions
Contacts and Locations
|1||Mayo Clinic in Arizona||Scottsdale||Arizona||United States||85259|
Sponsors and Collaborators
- Mayo Clinic
- Principal Investigator: Aqsa Khan, MD, Mayo Clinic
Study Documents (Full-Text)None provided.